Premium
Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting
Author(s) -
Gallagher David J.,
Milowsky Matthew I.,
Bajorin Dean F.
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23692
Subject(s) - medicine , bevacizumab , pemetrexed , oncology , cancer , trastuzumab , bladder cancer , chemotherapy , disease , cisplatin , intensive care medicine , breast cancer
Urothelial carcinoma (UC) remains a significant health problem affecting an estimated 68,810 people in 2008 alone in the US. The majority of patients with metastatic disease develop disease recurrence, and long‐term survival rates are poor. There is no standard of care for the treatment of patients with UC after the failure of cisplatin‐based regimens in the first‐line setting. Efforts to improve second‐line treatment have led to the evaluation of single agents such as vinflunine and pemetrexed, and multidrug combinations with cytotoxic and targeted agents, including trastuzumab and bevacizumab. The authors reviewed the activity of several single agents and combination regimens in patients with UC. Emerging strategies for the measurement of response in clinical trials were also outlined. Cancer 2008. © 2008 American Cancer Society.